Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Adcetris (brentuximab vedotin) is indicated for the treatment of previously untreated Stage III or IV classical Hodgkin lymphoma (cHL) in combination with doxorubicin, vinblastine, and dacarbazine, and for cHL at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation consolidation. It is also used for cHL after failure of auto-HSCT or at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates. Additionally, Adcetris treats systemic anaplastic large cell lymphoma (sALCL) and other CD30-expressing peripheral T-cell lymphomas, as well as primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) with prior systemic therapy.
• This summary is based on the review of 10 systematic review(s)/meta-analysis(es). ^[1-10]
• Brentuximab vedotin (BV) demonstrated a pooled overall response rate (ORR) of 62.6% and a complete response (CR) rate of 32.9% after four cycles in patients with relapsed/refractory classical Hodgkin lymphoma (R/R cHL).
• In R/R cHL patients post-autologous stem cell transplantation (ASCT), BV showed a 5-year overall survival (OS) of 34% and a 5-year progression-free survival (PFS) of 31%.
• Comparative analysis revealed that BV improved ORR by 22% compared to salvage chemotherapy in R/R cHL patients post-ASCT.
• Quality of life (QoL) outcomes were mixed for BV, with pembrolizumab and other PD-1 inhibitors providing more consistent improvements in QoL scores.
• Brentuximab vedotin (BV) is associated with common adverse events (AEs) including neutropenia (13.3-23%), anemia (8.8-39.0%), thrombocytopenia (4-4.6%), and grade ≥3 peripheral neuropathy (3.3-7.3%).
• BV increases the risk of all-grade and high-grade adverse events such as peripheral sensory neuropathy, pyrexia, nausea, vomiting, diarrhea, and alopecia compared to non-BV regimens.
• Pulmonary toxicity was more frequently observed with bleomycin-containing regimens, whereas peripheral neuropathy was linked to the cumulative dose of BV.
• BV-containing regimens demonstrated a 2-year PFS ranging from 47% to 84% in older adults with noted risks of pulmonary toxicity from bleomycin and peripheral neuropathy from BV.